Adaptively evolved human oral actinomyces‐sourced defensins show therapeutic potential

Adaptively evolved human oral actinomyces‐sourced defensins show therapeutic potential

Abstract The development of eukaryote‐derived antimicrobial peptides as systemically administered drugs has proven a challenging task. Here, we report the first human oral actinomyces‐sourced defensin—actinomycesin—that shows promise for systemic therapy. Actinomycesin and its homologs are only pres...

Full description

Bibliographic Details
Main Authors: Shunyi Zhu, Bin Gao, Yoshitaka Umetsu, Steve Peigneur, Ping Li, Shinya Ohki, Jan Tytgat
Format: Article
Language:English
Published: Springer Nature 2022-02-01
Series:EMBO Molecular Medicine
Subjects:
actinomycesin
adaptive evolution
antimicrobial peptide
cell‐wall synthesis inhibitor
systemic therapy
Online Access:https://doi.org/10.15252/emmm.202114499

Internet

https://doi.org/10.15252/emmm.202114499

Similar Items